Exposure-Response Relationship of Dostarlimab With Chemotherapy in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis Two of Part 1 of ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

[{"type":"text","required":true,"label":"Name","className":"form-control","name":"name","subtype":"text"},{"type":"text","subtype":"email","required":true,"label":"Email","description":"We will contact you using this email address.","className":"form-control","name":"email"},{"type":"textarea","required":false,"label":"How did you hear about us?","className":"form-control","name":"textarea-1704996600736","subtype":"textarea"},{"type":"text","required":false,"label":"Organization","className":"form-control","name":"company","subtype":"text"},{"type":"text","subtype":"tel","required":false,"label":"Phone","className":"form-control","name":"phone"},{"type":"text","required":false,"label":"Address","className":"form-control","name":"address","subtype":"text"},{"type":"text","required":false,"label":"State","className":"form-control","name":"state","subtype":"text"},{"type":"select","required":false,"label":"How did you hear about us?","className":"form-control","name":"select-1704996640121","values":[{"label":"Website","value":"Website","selected":true},{"label":"Work","value":"work","selected":false}]}]